Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Comparison of ticlopidine and cilostazol for the prevention of restenosis after percutaneous transluminal coronary angioplasty
Autore:
Nagaoka, N; Matsubara, T; Okazaki, K; Masuda, N; Shikaura, K; Hotta, N;
Indirizzi:
Nagoya Univ, Sch Med, Dept Internal Med 3, Showa Ku, Aichi 4668550, Japan Nagoya Univ Aichi Japan 4668550 al Med 3, Showa Ku, Aichi 4668550, Japan
Titolo Testata:
JAPANESE HEART JOURNAL
fascicolo: 1, volume: 42, anno: 2001,
pagine: 43 - 54
SICI:
0021-4868(200101)42:1<43:COTACF>2.0.ZU;2-L
Fonte:
ISI
Lingua:
ENG
Soggetto:
BALLOON ANGIOPLASTY; PLATELET-AGGREGATION; STENT IMPLANTATION; ARTERY DISEASE; PLACEMENT; HYPERPLASIA; INHIBITION; HEPARIN; ASPIRIN; IMPACT;
Keywords:
antiplatelet therapy; follow-up studies; quantitative coronary arteriography;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
31
Recensione:
Indirizzi per estratti:
Indirizzo: Matsubara, T Nagoya Univ, Sch Med, Dept Internal Med 3, Showa Ku, 65 Tsurumai Cho, Aichi 4668550, Japan Nagoya Univ 65 Tsurumai Cho Aichi Japan 4668550 68550, Japan
Citazione:
N. Nagaoka et al., "Comparison of ticlopidine and cilostazol for the prevention of restenosis after percutaneous transluminal coronary angioplasty", JPN HEART J, 42(1), 2001, pp. 43-54

Abstract

Prevention of restenosis after percutaneous transluminal coronary angioplasty (PTCA) continues to be a significant problem. Recent controlled studieshave demonstrated that cilostazol suppresses restenosis after PTCA. The effects of ticlopidine. another antiplatelet agent. were compared in terms ofoutcomes of patients randomized Ibr treatment with the two drugs after PTCA. A total of 35 patients (47 lesions) were assigned prospectively and randomly to ticlopidine (17 patients, 24 lesions) and cilostazol (18 patients, 23 lesions) groups. Minimal luminal diameter (MLD) and percentage of stenosis to reference diameter were estimated before PTCA, just after the procedure and after 4 months follow-up. All patients underwent 4 months angiographic follow-up, at the end of which MLD was 2.03 +/- 0.71 mm in the ticlopidine group and 2.05 +/- 0.68 mm in the cilostazol group (p = 0.95), and the percentage of stenosis to reference diameter was 31.4 +/- 16.7% and 30.0 +/-17.0%, respectively (p = 0.78). The restenosis rate was 12.5% in the ticlopidine group and 17.4% in the cilostazol group (p = 0.69), relatively low as compared to the 20% to 30% reported in previous studies. Adverse drug reactions during the follow-up period were observed in two of the ticlopidine group and none of the cilostazol group. We conclude that both ticlopidine and citostazol are effective for the prevention of restenosis after PTCA, however the former may be associated with slight side effects.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/09/20 alle ore 21:54:26